US10655157B2 - Microbial analysis - Google Patents

Microbial analysis Download PDF

Info

Publication number
US10655157B2
US10655157B2 US15/028,052 US201415028052A US10655157B2 US 10655157 B2 US10655157 B2 US 10655157B2 US 201415028052 A US201415028052 A US 201415028052A US 10655157 B2 US10655157 B2 US 10655157B2
Authority
US
United States
Prior art keywords
maldi
lipid
data
extraction
analysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/028,052
Other languages
English (en)
Other versions
US20160237469A1 (en
Inventor
Gerald STUBIGER
Omar BELGACEM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kratos Analytical Ltd
Original Assignee
Kratos Analytical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kratos Analytical Ltd filed Critical Kratos Analytical Ltd
Assigned to KRATOS ANALYTICAL LIMITED reassignment KRATOS ANALYTICAL LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BELGACEM, Omar, STUBER, GERALD
Assigned to KRATOS ANALYTICAL LIMITED reassignment KRATOS ANALYTICAL LIMITED CORRECTIVE ASSIGNMENT TO CORRECT THE LAST NAME OF THE FIRST INVENTOR PREVIOUSLY RECORDED ON REEL 038225 FRAME 0171. ASSIGNOR(S) HEREBY CONFIRMS THE EXECUTED ASSIGNMENT. Assignors: BELGACEM, Omar, STUBIGER, GERALD
Publication of US20160237469A1 publication Critical patent/US20160237469A1/en
Application granted granted Critical
Publication of US10655157B2 publication Critical patent/US10655157B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/02—Details
    • H01J49/04—Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
    • H01J49/0409—Sample holders or containers
    • H01J49/0418—Sample holders or containers for laser desorption, e.g. matrix-assisted laser desorption/ionisation [MALDI] plates or surface enhanced laser desorption/ionisation [SELDI] plates

Definitions

  • the present invention relates to a method of analysing microbes.
  • the analysis is based on lipid profiling, and can be used in microbial identification.
  • Mass spectrometry can be used to analyse biomolecules, typically using soft ionization techniques.
  • Matrix-Assisted Laser Desorption/lonization (MALDI)-MS is one such technique, and has been widely used in the analysis of large biomolecules including proteins. Protein fingerprinting has enabled the application of MALDI-MS for microbial identification and diagnostics.
  • Lipids are known to be structurally important within cells, and are the major components of cell membranes and other sub-cellular structures. They are active in major cellular mechanisms, and influence the properties and functionality of proteins.
  • microbes can vary greatly between different genera (e.g. bacteria, yeast, filamentous fungi), and even within a genus at the species level.
  • prokaryotic organisms e.g. bacteria
  • Gram+ and Gram ⁇ depending on the characteristics of their cell structures.
  • prokaryotes and eukaryotes all have a cytoplasmic membrane.
  • Phospholipids (particularly glycerophospholipids and phosphosphingolipids) are known to be the major membrane lipids of many microbes. Indeed, components of phospholipid biosynthesis and the PLs themselves are membrane bound and serve as the precursors of other cell membrane components. [1]
  • cationic phosphatidylcholine accounts for about 50% of total membrane lipids in eukaryotes alongside phosphatidylserine (PS) and phosphatidylinositol (PI) as minor components.
  • Zwitterionic phosphatidylethanolamine (PE), anionic phosphatidylglycerol (PG) and/or cardiolipin (CL) represent the major membrane lipids of most known bacteria (e.g. up to 80% PE in E. coli ).
  • Other significant PLs are amino acid esters of PG (e.g. lysyl -, alanyl-,or ornithyl-PG) [14] .
  • NLs neutral lipids
  • DAGs diacylglycerols
  • TAGs triacylglycerols
  • CEs cholesteryl esters
  • NLs are known to also play an important role in cell membrane functionality.
  • CEs are only rarely found in prokaryotes (i.e. bacteria) they are more common lipid components of eukaryotes (i.e. yeasts, fungi and mammalian cells). These lipid molecules contain 1-3 fatty acids esterified to a glycerol or sterol backbone.
  • a significant group of NLs is the glycosyl diglycerides (e.g. digalactosyldiglyceride, DGDG), which are found mainly in Gram+ bacteria (e.g. Bacillus spp.) [14] .
  • PLs and NLs
  • homeostasis of the lipid composition is very important to sustain the cell membrane integrity and functionality (e.g. trans-membrane signalling, intercellular interactions, energy metabolism, cell proliferation, etc.) of microbial cells and their viability in different environments.
  • alterations to cellular PL compositions can result from exposure of microbes to environmental stresses, such as extreme temperatures, toxic substances, food additives and antibiotics.
  • microbial cells possess a very characteristic, evolutionary based phospholipid composition that can be used for chemotaxonomic purposes, whereby small differences in the phospholipid profiles can potentially be exploited for differentiation at the strain level. This allows for strains with certain characteristics to be identified, including those that are pathogenic and resistant to antibiotics.
  • Microbial phospholipid compositions are very complex, and are typically analysed using mass spectrometry (MS) because it allows the simultaneous detection of many individual molecular species within a single MS spectrum.
  • MS mass spectrometry
  • One of the first examples of using MS for the classification of microorganisms was the use of gas-chromatography (GC)-MS.
  • GC-MS is used for cellular fatty acid analysis because of its good chromatographic separation potential.
  • lipids need to be broken down into constituent fatty acid molecules to be analysed, and thus the phospholipid composition within the cells cannot be determined.
  • MALDI-MS is generally a preferred soft-ionisation technique. Data can be obtained simply and quickly, and is relatively simple to analyse because the molecules are almost exclusively detected as singly charged ions upon laser irradiation of the matrix-embedded samples. Further the instruments used are robust and reliable allowing the analysis of crude (i.e. unpurified) samples. Consequently, MALDI-MS has developed into a routine technique for microbial diagnostics based on “protein fingerprinting”. [13]
  • MALDI-MS has been reported as a method for bacterial phospholipid analysis. [14][15] However, a lack of reliable sample preparation protocols and instrumentation techniques has prevented wider application of these methods. Routine bacterial identification by phospholipid analysis using MALDI-MS has not been possible for closely related bacteria, preventing its use in taxonomy. Moreover, no successful lipid MALDI-MS analysis has been reported for other types of microbe (e.g. yeasts and fungi), which must still be identified by cell morphology using light microscopy, genotyping, and/or protein fingerprinting.
  • yeasts and fungi e.g. yeasts and fungi
  • MALDI-MS based phospholipid profiling Furthermore, differentiation of microbial strains (within a species) using MALDI-MS based phospholipid profiling has not been reported. Nor has MALDI-MS based lipid profiling of yeasts or fungi.
  • the present invention provides a method of microbial analysis that can differentiate microbial strains based on the constituent lipid analysis.
  • the methods use MALDI mass spectrometry.
  • the method analyses microbial phospholipids.
  • the method also analyses microbial proteins.
  • protein fingerprinting” and “lipid fingerprinting” can be performed on the same microbes. Indeed, the same extraction process can be used to obtain extracted lipids and extracted proteins. This facilitates subsequent MALDI-MS analysis, and that analysis can include merging the data from lipid and protein m/z ranges.
  • the data from this analysis can be used to simply and reliably identify microbial strains.
  • the invention provides a method of identifying microbial strains, the method comprising;
  • microbes can be identified at the strain level. Similar, closely-related microbes can be differentiated using the method devised by the inventors.
  • lipid profiling can be used to identify microbial strains.
  • the inventors have determined that lipid profiles recorded from bacterial cell cultures at certain time points (e.g. after 24 or 72 hours) or using certain culture media (e.g. blood or minimal agar) allow reliable differentiation of bacterial stains. Consequently, the presently claimed method allows chemotaxonomic identification at the sub-species level, and has been devised to increase the signal to noise ratio and mass spectral reproducibility, amongst other factors.
  • the claimed method is simple, fast, easy and reliable.
  • the method is particularly useful in the clinical/hospital environment where very large numbers of tests (to identify microbe information) are carried out and it is important to have high confidence in the result.
  • the method includes obtaining mass spectrometry data for proteins as well as for lipids (e.g. phospholipids). That is, suitably the method includes “protein fingerprinting” as well as “lipid fingerprinting” so as to differentiate microbial strains.
  • lipids suitable including phospholipids
  • Suitably extraction step i) includes extraction of proteins from the microbe.
  • lipids and proteins are extracted using the same extraction composition (e.g. MeOH or MeOH/H 2 O). As discussed below, this facilitates high throughput analysis because only one extraction composition is required in order to access both lipid information and protein information.
  • sample preparation step ii) includes a) preparation of a MALDI sample incorporating the extracted lipids, and b) preparation of a MALDI sample incorporating the extracted proteins.
  • steps ii) a) and ii) b) use different MALDI matrix materials.
  • Suitably data gathering step iii) includes obtaining mass spectrum data for the extracted lipids and obtaining mass spectrum data for the extracted proteins.
  • the mass spectrum data for the lipids and the mass spectrum data for the proteins can be combined/merged.
  • the invention provides a method of analysing microbes, the method comprising;
  • the second aspect allows different spectra to be obtained for different microbes.
  • suitably extraction step i) includes extraction of proteins from the microbe.
  • the lipids and the proteins are extracted using the same extraction composition.
  • sample preparation step ii) may include a) preparation of a MALDI sample incorporating the extracted lipids and, b) preparation of a MALDI sample incorporating the extracted proteins.
  • steps ii) a) and ii) b) use different MALDI matrix materials.
  • suitably data gathering step iii) includes obtaining mass spectrum data for the extracted lipids and obtaining mass spectrum data for the extracted proteins.
  • the mass spectrum data for the lipids and the mass spectrum data for the proteins can be combined/merged.
  • the invention provides a method of analysing microbes, the method comprising;
  • the alcohol or ether based solvents used in the third aspect allows lipid MS spectra to be obtained, in which sub-species resolution can be reliably achieved for all microbe types.
  • the extraction composition comprises more than 50 vol % alcohol.
  • US 2012/0197535 uses Folch reagents to extract glycolipids, and describes subsequent sub-species differentiation.
  • glycolipids are not present in all microbes.
  • the inventors' alcohol-based solvent extraction has been designed to allow the extraction of lipids from all microbes, wherein the MS spectrum of the extracted lipids allows subsequent sub-species resolution.
  • the alcohol-based solvent used in the lipid extraction step will also dissolve the matrix material to allow sample preparation. This avoids the need for extra reagents, which reduces the cost, and results in a cleaner, more reproducible spectrum in which sub-species can be differentiated. In other words, the alcohol-based solvents used in the lipid extraction are much more compatible with the matrix materials than the Folch reagents.
  • the lipid extraction step extracts phospholipids.
  • the alcohol-based solvent used in the extraction step has been specifically tailored to this end, i.e. to allow phospholipid extraction, in such a manner as to allow sub-species resolution.
  • the tailored solvent system is not only effective to extract lipids (especially phospholipids) but also proteins. This permits protein fingerprinting and lipid fingerprinting using the same extract.
  • extraction step i) includes extraction of proteins from the microbe.
  • the lipids and the proteins are extracted using the same extraction composition.
  • the extraction step i) includes adding water to the microbes (e.g. to the culture). This can be a precursor step before the addition of the extraction composition.
  • the extraction composition may comprise water.
  • an alcohol/water or ether/water mixture can be used.
  • water is added to the microbes in a first (precursor) step followed by addition of alcohol (suitably methanol) in a second step.
  • sample preparation step ii) may include a) preparation of a MALDI sample incorporating the extracted lipids and, b) preparation of a MALDI sample incorporating the extracted proteins.
  • steps ii) a) and ii) b) use different MALDI matrix materials.
  • suitably data gathering step iii) includes obtaining mass spectrum data for the extracted lipids and obtaining mass spectrum data for the extracted proteins.
  • the mass spectrum data for the lipids and the mass spectrum data for the proteins can be combined/merged.
  • the invention provides a method of analysing microbes, the method comprising;
  • suitably extraction step i) includes extraction of proteins from the microbe.
  • the lipids and the proteins are extracted using the same extraction composition.
  • the (lipid and protein) extraction step may comprise addition of water and alcohol (suitably selected from methanol or ethanol, preferably methanol), sequentially (suitably water first) or as a water-alcohol mixture.
  • alcohol suitably selected from methanol or ethanol, preferably methanol
  • sample preparation step ii) may include a) preparation of a MALDI sample incorporating the extracted lipids and, b) preparation of a MALDI sample incorporating the extracted proteins.
  • steps ii) a) and ii) b) use different MALDI matrix materials.
  • CHCA matrix material is used for the extracted proteins. That is, the sample preparation step (e.g. step ii) b)) includes addition of CHCA matrix material to the extracted proteins.
  • suitably data gathering step iii) includes obtaining mass spectrum data for the extracted lipids and obtaining mass spectrum data for the extracted proteins.
  • the mass spectrum data for the lipids and the mass spectrum data for the proteins can be combined/merged.
  • the lipid extraction step extracts at least phospholipids.
  • the data gathering step further includes scanning in the m/z range from about 2000 to about 20000 in the MS1 spectrum.
  • the m/z range scanned is for protein analysis as well as for lipid analysis.
  • the data gathering step may include 1) performing MALDI-MS on the MALDI sample prepared according to step ii) a), and 2) performing MALDI-MS on the MALDI sample prepared according to step ii) b).
  • the same microbe sample is processed (extraction, MALDI sample preparation) so as to obtain m/z data for both lipid composition and for protein composition. This permits even higher confidence and reliability in the assignment of sub-species information for a microbe (e.g. a culture).
  • the invention provides a method of analysing non-bacterial microbes, the method comprising;
  • suitably extraction step i) includes extraction of proteins from the microbe.
  • the lipids and the proteins are extracted using the same extraction composition.
  • sample preparation step ii) may include a) preparation of a MALDI sample incorporating the extracted lipids and, b) preparation of a MALDI sample incorporating the extracted proteins.
  • steps ii) a) and ii) b) use different MALDI matrix materials.
  • suitably data gathering step iii) includes obtaining mass spectrum data for the extracted lipids and obtaining mass spectrum data for the extracted proteins.
  • the mass spectrum data for the lipids and the mass spectrum data for the proteins can be combined/merged.
  • the invention provides a method of analysing microbes, the method comprising;
  • the mass spectrum data for the lipids and the mass spectrum data for the proteins can be combined/merged.
  • the method includes iv) a microbe identification step, comprising analysis of the mass spectrometry data to characterise or identify the microbe, preferably the microbial strain.
  • a microbe identification step comprising analysis of the mass spectrometry data to characterise or identify the microbe, preferably the microbial strain.
  • any such analysis is performed on the merged mass spectrum data.
  • the sample preparation step ii) typically includes preparing one MALDI sample for protein analysis (using e.g. CHCA as matrix material) and one (a different) MALDI sample for lipid analysis (using e.g. ATT or 9AA as matrix material).
  • the composition typically a suspension obtained from the extraction step is used to prepare both the MALDI sample for protein analysis (e.g. by addition of a suitable matrix material such as CHCA) and the MALDI sample for lipid analysis (e.g. by addition of a suitable matrix material such as ATT or 9AA).
  • the lipid extraction step comprises extraction of phospholipids.
  • at least about 20 vol %, preferably 40 vol %, 50 vol %, 60 vol %, 70 vol % or 80 vol % of the extracted lipids are phospholipids.
  • at least about 20 vol %, preferably 40 vol %, 60 vol % or 80 vol % of phospholipids in the sample are extracted.
  • the lipid extraction step comprises extraction of proteins.
  • the data gathering step includes obtaining mass spectrum data for lipids (typically by scanning in the m/z range 100 to 3000, for example 200 to 2000) and for proteins (typically by scanning in the m/z range 2000 to 20000),
  • the method of the second, third, fourth and fifth aspects may further comprise a microbe identification step, comprising analysis of the mass spectrometry data to characterise or identify the microbe.
  • the microbe identification step includes analysis of protein mass spectrometry data (typically including data obtained from some or all of the m/z range 2000 to 20000) as well as analysis of lipid mass spectrometry data (typically including data obtained from some or all of the m/z range 100 to 3000, typically 200 to 2000).
  • protein mass spectrometry data typically including data obtained from some or all of the m/z range 2000 to 20000
  • lipid mass spectrometry data typically including data obtained from some or all of the m/z range 100 to 3000, typically 200 to 2000.
  • the method of any aspect may further comprise a further, initial, microbe cultivation step.
  • a further aspect of the inventions pertains to a kit for implementing a method of any previous aspect.
  • the kit comprises reagents necessary to implement the method, and a detailed protocol explaining each step in the method.
  • the kit comprises one or more of:
  • the matrix material is selected from ATT, THAP and 9AA. and/or the optional co-matrix material is selected from DAHC, GUA and sodium or lithium acetate, and/or two or more sample plates (e.g. 16 sample plates) are included, wherein each is a 48-well target slide (e.g. FlexiMassTM-DS target slide), and/or organic solvents for lipid extraction and/or matrix material dissolution are included.
  • a 48-well target slide e.g. FlexiMassTM-DS target slide
  • organic solvents for lipid extraction and/or matrix material dissolution are included.
  • the MALDI matrix material is suitably selected from ⁇ -Cyano-4-hydroxycinnamic acid (CHCA), sinapinic acid (SA) and ferulic acid (FA). CHCA is preferred.
  • the kit can include a first matrix material for lipid analysis, and a second matrix material (different from the first matrix material) for protein analysis.
  • the kit includes a container or enclosure in which the reagents and/or other components are located.
  • any lipid extraction technique can be used that conserves the lipids, preferably at least the phospholipids, intact. This preserves the full biological information content.
  • the lipid extraction step comprises extraction of lipids from the microbial cells.
  • the lipid extraction technique comprises extraction of phospholipids from microbial cells.
  • neutral lipids are preferably also extracted.
  • the lipid extraction step comprises addition of an organic extraction composition to the microbes.
  • the organic extraction composition preferably comprises one or more organic solvents.
  • the organic extraction composition preferably comprises one of more alcohols.
  • the organic extraction composition preferably comprises more than about 50 vol % alcohol, more preferably at least about 51 vol %, 52 vol %, 53 vol %, 54 vol %, 55 vol %, 60 vol %, 70 vol %, 80 vol % or 90 vol %.
  • Short-chain alcohols are preferred, such as C 1-4 alcohols, with ethanol and methanol particularly favoured because they have been found to effectively extract PLs from all types of microbial cells (i.e. bacteria, yeasts and fungi), independent of the cellular structure.
  • the extraction composition comprises up to 100 vol % alcohol, preferably up to 95 vol %, 90 vol %, 85 vol %, 80 vol %, 75 vol % or 70 vol %.
  • the organic extraction composition may alternatively or additionally comprise ketones, esters, and/or ethers (e.g. MTBE, DIPE), or mixtures thereof.
  • solvents are preferred because they are compatible with (i.e. they readily dissolve) the MALDI matrix materials used in the sample preparation step. For this reason, the alcohol based solvents (which comprise at least about 50 vol % alcohol) are particularly favoured. As a result of this compatibility, these solvents generate relatively small background noise signals in the resultant mass spectra. Lipid (and particularly phospholipid) extraction is efficient and reliable, allowing for reproducible spectra to be obtained. Further, no additional reagents are needed, saving cost.
  • the extraction composition is not bi-phasic. In other words, it entirely comprises either polar solvents, or non-polar solvents. No separation step is then necessary, reducing processing time and increasing throughput.
  • the lipid extraction step simply comprises addition of the solvent to the sample, i.e. it is a single step extraction method. This is in contrast to the Folch reagents, which require the polar and non-polar components to be phase separated after lipid extraction.
  • the extraction composition does not include any halogenated organic solvent. That is, chloroform (CHCl 3 ) is specifically not part of the extraction composition.
  • the extraction composition comprises less than 5 vol %, preferably less than 4 vol %, 3 vol %, 2 vol %, 1 vol %, 0.5 vol %, 0.4 vol %, 0.3 vol %, 0.2 vol % or 0.1 vol % of any halogenated organic compounds or solvents (including chloroform).
  • the organic extraction composition preferably comprises or consists of alcohols, as they result in the smallest spectral noise.
  • C 1-4 alcohols are favoured, and methanol is particularly preferred.
  • the organic solvent may substantially consist of methanol.
  • the organic extraction composition preferably comprises or consists of an alcohol/ketone mixture, preferably in a ratio by volume of from about 70:30 or 75:25 to about 85:15 or 90:10.
  • the organic extraction composition comprises a C 1-4 alcohol and a C 3-4 ketone mixture, in that ratio range.
  • the organic extraction composition comprises of a methanol/acetone mixture, in that ratio range.
  • the organic extraction composition consists of a methanol/acetone mixture in a ratio by volume of from about 70:30 or 75:25 to about 85:15 or 90:10.
  • mixtures are particularly preferred because they effectively extract a diverse range of lipid classes which have different polarities (including cationic and anionic phospholipids, and neutral lipids), whilst minimising spectral noise and allowing reproducible spectra to be obtained.
  • the organic extraction composition comprises more than 50 vol % ether, preferably at least about 55 vol %, 60 vol %, 70 vol %, 80 vol % or 90vol %.
  • C 1-4 ethers are preferred (by which we mean, the carbon chain on either side of the ether linkage contains a between 1 and 4 carbons).
  • the ether volume comprises or consists of diisopropylether (DIPE).
  • DIPE diisopropylether
  • the ether-based organic extraction composition may additionally comprise alcohols, ketones and/or esters, or mixtures thereof.
  • the extraction step may include the use of water, either as part of the extraction composition or as a precursor step in which water is added to the microbes.
  • the extracted sample is treated to remove contaminants such as proteins.
  • contaminants such as proteins.
  • this optional contaminant removal treatment is either not carried out or is adjusted so as to preserve (or at least minimise removal of) proteins.
  • proteins contaminants these are preferably precipitated out of the extracted solution and removed by centrifugation.
  • the present inventors have found that, surprisingly, the extraction methods and solvent systems discussed herein in respect of lipid extraction are also effective to extract proteins from the microbes and to permit the extracted proteins to be analysed by MALDI mass spectrometry.
  • the present inventors have found that the use of water, in addition to the alcohol/ether components of the extraction composition, can assist in facilitating the availability of proteins for subsequent MALDI-MS analysis. This can be achieved by combining/mixing water with the microbe (e.g. with the cell culture). This can be done in a first/precursor step before combining/mixing with the alcohol/ether components and/or by including water in the alcohol/ether extraction composition.
  • the present inventors have found that use of water assists in preparing a suspension (of the microbe material) which facilitates formation of a good quality MALDI sample.
  • swelling and/or spreading out and/or dispersion of the microbes can be assisted by the use of water, especially in a first/precursor step prior to combining/mixing with alcohol/ether.
  • the resultant material is sonicated.
  • (ultra)sonication is carried out for at least 1 minute, suitably at least 2 minutes, preferably at least 5 minutes.
  • sonication is carried out for no more than about 20 minutes, typically no more than 15 minutes. A particularly preferred range is 5 to 10 minutes.
  • the composition comprising the extracted lipids and/or proteins can be cooled, for example to ⁇ 20° C., for example to ⁇ 10° C., for example to ⁇ 5° C.
  • This can conveniently be achieved by placing the sample (in a suitable container/vessel) on/in ice.
  • the present inventors have found that this can further enhance the quality of the extract for subsequent MALDI-MS analysis.
  • the duration of any such cooling step is typically at least 10 minutes, suitably at least 20 minutes, and preferably at least 25 minutes.
  • the cooling step is no longer than 60 minutes, typically no more than 45 minutes, and preferably no more than 35 minutes. In embodiments, cooling is for about 30 minutes.
  • composition comprising extracted lipids and/or proteins can optionally be vortexed. Generally this is done in combination with, suitably after, cooling as discussed above. Again, this has been found to further improve the homogeneity of the suspension formed from the addition of the extraction composition to the microbes, which in turn improves the quality of the MALDI-MS spectra.
  • the sample preparation step comprises addition of the extracted lipids to a matrix material.
  • the sample preparation step comprises addition of the extracted proteins to a matrix material.
  • the matrix material used for lipid analysis can be different to the matrix material used for protein analysis.
  • the matrix used in MALDI-MS acts a) as an ionization promoter of the lipid molecules and b) as an ionisation moderator to prevent fragmentation of the relatively labile lipid molecules.
  • the matrix selected is not particularly limited, provided that this function is realised.
  • 2,5-dihydroxybenzoic acid (2,5-DHB), 2,4-dihydroxybenzoic acid (2,4-DHB), 6-aza-2-thiotymine (ATT), 9-aminoacridine (9AA) and 2,4,6-trihydroxyacetophenone (THAP) are all suitable matrix materials. That is, in some cases the matrix material comprises one or more of these compounds.
  • the matrix used may depend on whether the mass spectrometer is operated in the positive or negative mode. That is, whether the lipids will be positively or negative ionised.
  • Some example matrix materials are discussed below, which are particularly preferred when working with phospholipids (and neutral lipids where they are also extracted).
  • THAP 2,4,6-trihydroxyacetophenone
  • concentration range of the salt doping is preferably about 1-50 mM, preferably 10-20 mM. Doping at these levels allows complete suppression of other unwanted alkali counter ions within the MALDI mass spectra.
  • 6-aza-2-thiotymine is a preferred matrix material when operating in the positive mode. This is particularly good for the detection of cationic PLs. ATT results in a softer ionization than THAP, and leads to less pronounced generation of fragmentation products, and so the resultant spectra are easier to analyse. It is particularly preferred when doped with di-ammonium hydrogen citrate (DAHC), which suppresses the formation of mixed alkali adducts (e.g. Na or K) and allows for detection of exclusively protonated PLs (See FIG. 3 ).
  • DAHC di-ammonium hydrogen citrate
  • the concentration range of the salt doping is preferably about 1-100 mM, more preferably 10-50 mM. Doping at these levels allows exclusive detection of protonated molecular ions within the MALDI mass spectra.
  • ATT is preferred to THAP, because ATT can be used with ionising lasers which have a greater range of wavelengths (i.e. ATT is compatible with a greater range of lasers).
  • 9-aminoacridine (9AA) is a preferred matrix material when operating in the negative mode. This is particularly good for the detection of anionic PLs.
  • 9AA doped with guanidine-HCl (9AA-GUA) or doped with pyridine (9AA-PYR) are particularly preferred, because the sensitivity of detection is increased and clear, reproducible spectra result (See FIG. 3 ).
  • the 9AA-GUA preferably comprises from about 3 mM or 4 mM to about 6 mM or 7 mM of guanidine, most preferably about 5 mM.
  • the 9AA-PYR preferably comprises about 0.3 vol % or 0.4 vol % to about 0.6 vol % or 0.7 vol % of pyridine, most preferably about 0.5 vol %.
  • the dopants each modulate the contribution of alkali salt adducts in the resultant mass spectra, and promote the detection of [M+H] + and [M ⁇ H] ⁇ ions in the positive and negative modes respectively.
  • a solution of the extracted lipids is added to a solution of the matrix material.
  • the lipid solution preferably has a lipid concentration of from about 0.5 or 1 to about 10 or 20 ⁇ M, to provide the best mass spectral quality and reproducibility.
  • the matrix material solution is added to the microbial sample directly.
  • the solvent used to dissolve the matrix material extracts lipids from the microbial sample, which then form a MALDI sample with the matrix material.
  • This technique allows so called “on-target” lipid extraction; that is, lipid extraction on a MALDI sample plate. This is a faster processing technique and thus allows a higher analysis throughput.
  • the molar ratio of matrix material to lipids is suitably from about 50000:1 to about 2500:1.
  • the MALDI matrix material is suitably selected from ⁇ -Cyano-4-hydroxycinnamic acid (CHCA), sinapinic acid (SA) and ferulic acid (FA). CHCA is preferred.
  • the MALDI sample is preferably from about 0.5 ⁇ L to about 1.5 ⁇ L in volume, most preferably about 1 ⁇ L.
  • the sample is prepared on a polymeric or plastics MALDI sample plate, rather than a conventional steel target.
  • a polymeric or plastics MALDI sample plate rather than a conventional steel target.
  • 48-well FlexiMassTM-DS (Shimadzu) target slides can be used.
  • Data can be gathered with a mass spectrometer operating in the positive mode (positive ionisation of the sample) and/or the negative mode (negative ionisation of the sample).
  • the negative mode is preferred for the following reasons:
  • the m/z range scanned is preferably from about 100 to about 3000. This wide range allows detection of both intact lipids (typically m/z >500) and fatty acid residues (m/z typically ⁇ 500).
  • the method may be characterised in that the m/z range includes the range ⁇ 500, for example about 100 to ⁇ 500. More preferred m/z ranges may be from about 200, 300, 400 or 450 to about 1500, 1800, 2000, 2500 or 2800.
  • the m/z range includes the range from about 100 to about 500, suitably about 100 to ⁇ 500, preferably about 100 to about 450, more preferably about 100 to about 400.
  • the data gathering step of the method includes scanning the m/z range for protein information, typically from about 2000 to 20000. Typically this is done as a separate step, i.e. a MALDI-MS experiment, such that in embodiments the data gathering step comprises two stages—one for scanning the m/z range for lipids (and preferably also fatty acids), and one for scanning the m/z range for proteins.
  • the mass spectrum data for the lipids and the mass spectrum data for the proteins can be combined/merged. This can be achieved by exporting the protein and lipid data sets to a spreadsheet such as Micorsoft Excel and merging them. Cluster and/or other analysis can then be carried out as discussed herein.
  • a polymeric or plastics MALDI sample plate (rather than a conventional metal target) is used in preferred cases.
  • Lipid peaks in mass spectra are detected in a similar mass range to background signals.
  • high resolution instruments and techniques are preferably used.
  • one or more of the following mass spectrometry techniques may be used during the data gathering step:
  • CID collision induced dissociation
  • MSn multistage tandem mass spectrometry
  • MSn also allows both lipid profiling in the MS1 mode and structural elucidation of the individual lipid species mainly in the MS2 or MS3 modes.
  • the data gathered is analysed to identify or characterise the microbial strain.
  • The may comprise comparison of the data with existing data libraries.
  • These libraries may contain lipid mass fingerprints and/or protein mass fingerprints for microbial strains.
  • the microbe strain is definitively identified.
  • the microbe can be characterised based on its lipid profile and preferably also its protein profile. Certain properties, such as susceptibility to antibiotics and pathogenicity can be predicted or determined.
  • the microbes may be cultivated prior to lipid extraction.
  • Microbial lipid compositions are known to change over time.
  • the cultivation step follows a fixed procedure.
  • microbial strains may be cultivated in liquid or on solid culture media. Alternatively, they may be cultivated using blood agar or minimal medium (e.g. LB Agar). Blood agar is a preferred medium for bacterial cell culture, because it contains all necessary nutrients and bacterial growth is faster. In this case, the use of the negative ionisation mode is preferred, to minimise noise signals originating from the culture medium.
  • yeast strains may be grown on a GYP (glucose, yeast extract, peptone) medium.
  • GYP glycose, yeast extract, peptone
  • filamentous fungi may be grown on a Malt extract agar.
  • the cultivation period and environmental conditions are preferably the same in the sample cultivation as those used in the obtaining of any comparative data.
  • the cultivation may last for a fixed period of time. This may be 12 hours, 24 hours, 36 hours, 48 hours, 72 hours or longer. The precise length of time is not particularly important.
  • The, environmental conditions during cultivation are preferably as follows; from about 15° C. or 20° C. to about 25° C. or 37° C.
  • the cultivation preferably takes place in air.
  • FIG. 3 shows three MALDI-MS spectra obtained using different matrix substances optimised for the detection of NLs (TRAP-Na matrix), cationic PLs (ATT-DC matrix) and anionic PLs (9AA-GUA matrix).
  • FIG. 4 compares the relative signal strengths resulting from various lipid classes in (A) positive ionisation mode and (B) negative ionisation mode, and using three different matrix substances.
  • FIG. 5 shows two lipid MALDI-MS spectra obtained from blood agar, one obtained in the positive ionisation mode (bottom trace), and one in the negative ionisation mode (top trace).
  • FIG. 6A shows a lipid MALDI-MS spectrum obtained on an E. coli strain detected in the negative ionisation mode. This is the MS1 spectrum in the range m/z 500-800 displaying data representative of intact PLs. The inset shows the same spectrum in the range m/z 240-310 displaying data representative of FA fragment ions.
  • FIG. 6B shows the MALDI-MS/MS spectra of the three major lipid species at m/z 688, 702, and 716 of the same E. coli strain as used in FIG. 6A .
  • the data was obtained by tandem mass spectrometry. These are MS2 spectra, and allow the individual lipids to be identified.
  • FIG. 7B shows lipid MALDI-MS spectra obtained in the negative mode for the same 4 different microbes (trace order is the same as FIG. 7A ).
  • FIG. 8A shows a cluster analysis based on positive mode MALDI-MS data for all of the microbes listed in table 1.
  • FIG. 8B shows a cluster analysis based on negative mode MALDI-MS data for all of the microbes listed in table 1.
  • FIG. 9 shows negative mode MALDI mass spectra displayed in (A) the m/z range 240-310 and (B) 650-800 of four E. coli strains from Table 1.
  • FIG. 10 shows a cluster analysis based on negative mode MALDI-MS data for the bacterial strains listed in Table 1.
  • FIG. 11 shows a minimal spanning tree (MST) illustrating the relative relatedness of the bacterial strains listed in Table 1.
  • FIGS. 12A to C show the lipid profiles of four independent MALDI-MS measurements of A) NLs detected in the positive mode, B) cationic PLs detected in positive mode and C) anionic PLs detected in negative mode, respectively.
  • FIG. 13 is a schematic of an “all in one” microbe identification approach comprising preparation, from the same microbes (cell culture), of a MALDI sample for lipid analysis and a MALDI sample for protein analysis, and subsequent MALDI-MS measurements on both samples.
  • FIG. 14A shows a ( ⁇ )MALDI ⁇ MS spectra of Gram( ⁇ ) E. coli DH5D: 9AA matrix (upper trace after 5-10 minutes ultrasonication; lower trace after cooling and vortexing).
  • FIG. 14B shows ( ⁇ )MALDI ⁇ MS spectra of Gram (+) S. aureus: 9AA matrix (upper trace after 5-10 minutes ultrasonication; lower trace after cooling and vortexing).
  • FIG. 14C shows (+)MALDI ⁇ MS spectra of S. aureus : ATT matrix (upper trace after 5-10 minutes ultrasonication; lower trace after cooling and vortexing).
  • FIG. 15 shows ( ⁇ )MALDI ⁇ MS spectra of K. pneumoniae using different extraction solvents (upper trace EtOH; middle trace MeOH; and lower trace Folch).
  • FIG. 16 shows protein typing results of K. pneumoniae and E. Coli using (A) extraction methods of the present application; and (B) directly from cell culture.
  • FIG. 17 shows ( ⁇ )MALDI ⁇ MS spectra of different E. coli strains (using MALDI-QIT-TOF detection) (upper trace EPEC E2347; second trace EIEC E35990; third trace 12 M050679 [ E. Coli fully sensitive]; and lower trace DH5 Alpha E. Coli ).
  • FIG. 18 shows ( ⁇ )MALDI lipotyping cluster analysis (m/z 200-900 Selected Peaks).
  • FIG. 19 shows protein typing results for yeasts and filamentous fungi (Saramis).
  • FIG. 20 shows (+)MALDI ⁇ MS spectra of different yeasts and fungi (using MALDI-TOF detection) (upper trace Saccharomyces cerevisiae ; second trace Penicillium expansum ; third trace Aspergillus ochraceus ; and lower trace Aureobasidium pullulans ).
  • FIG. 21 shows (+)MALDI lipotyping cluster analysis.
  • FIG. 22 shows MALDI-MS spectrum of K. Pneumoniae in the protein m/z range, corresponding to the protein analysis of FIG. 16 .
  • FIG. 23 shows MALDI-MS spectrum of E. Coli DH5D in the protein m/z range, corresponding to the protein analysis of FIG. 16 .
  • Strains 6a and 6b are a mixed culture of S. haemolyticus and C. Striatum .
  • Strains 7 and 8 are antibiotic sensitive, strains 9 and 10 are antibiotic resistant and strains 11, 12 and 13 are enteropathogenic E. coli strains. Antibiotic resistance was tested against 17 different compounds based on determination of the minimum inhibitory concentration (MIC) value.
  • Strain number Strain identification 1 ACTCC 22913 S. aureus 2 ACTCC 2912 E. faecalis 3 ACTCC 12228 S. epidermis 4 ACTCC 13047 E. cloacae 5 ACTCC 27853 P. auruginosa 6a 12M203885 S.
  • 9 yeas strains were also cultivated. They belong to Saccharomyces cerevisiae and Saccharomyces kudriavzevii , and were grown on a GYP (glucose, yeast extract, peptone) medium for three days at room temperature (25° C.).
  • GYP glycose, yeast extract, peptone
  • Filamentous fungi (Hyphomycetes) were also cultivated.
  • the fungi belong to Aureobasidium, Aspergillus, Penicillium, Trichoderma, Wallemia and Mucor , and were grown on a Malt extract agar plate for one week at room temperature (25° C.).
  • 6-aza-2-thiotymine (ATT) dissolved in Ethanol (EtOH):H 2 O 90:10 (v/v) containing 10 mM diammoniumhydrogen citrate (DAHC) was used for detection of cationic phospholipids (e.g. PC, SM).
  • Ethanol Ethanol
  • DAHC diammoniumhydrogen citrate
  • a small volume (e.g. 0.3-0.5 ⁇ L) of the matrices at a concentration of 10 g/L was spotted on the MALDI target surface immediately followed by an equal volume of the microbial lipid extracts.
  • This known “dried droplet technique” is flexible and fully automatable sample application method for the analysis of lipids. [17] .
  • FlexiMassTM-DS Shiadzu, Manchester, UK 48-well disposable polymeric target slides were used as sample support because they provide optimal performance without producing any interfering background noise in the low mass range (i.e. m/z ⁇ 1000) compared to conventional stainless steel targets.
  • the matrix solution consists of 1 ml of a saturated CHCA solution in 33/33/33 acetonitrile/ethanol/water containing a final concentration of 3% TFA.
  • Preparation Weigh out approximately 40 mg of CHCA. Dissolve in 1 mL 33/33/33 acetonitrile/ethanol/water containing a final concentration of 3% TFA (prepared previously). Mix using a vortex. At room temperature, this should result in a saturated solution; centrifuge or allow any undissolved solid to settle.
  • the MALDI analysis steps is the same as for lipid analysis except the mass range is different (2000-22000 Max) and in positive mode.
  • RTOF MALDI-reflectron-TOF
  • the ion accelerating voltage was set to 20 kV and the reflectron analyser was operated at 25 kV. Measurements were performed in the positive (+) or negative ( ⁇ ) ionization mode using delayed ion extraction for baseline monoisotopic mass resolution of the peaks.
  • the laser energy was adjusted to 10-20% above the threshold of laser irradiation (power 90-100) according to the manufacturer's nominal scale (power 180 at maximum), whereby a circular laser raster ( ⁇ 500-1000 ⁇ m diameter) adjusted to the morphology of the matrix spots on the target surface was used.
  • a hierarchical cluster analysis was performed in order to establish a dendrogramme displaying the relatedness of the different microbial species based on their lipid/protein profiles using the commercially available statistics software packages DataLab 3.5 (http://www.lohninger.com/datalab) and BioNumerics 7.1 (Applied Maths, Belgium). In case of DataLab the Euclidean distance measure was used and the Linkage type was based on the Ward's method.
  • MALDI-MS data was processed. Firstly, MALDI data of each individual organism were exported as a so-called “mass list” containing m/z values and the corresponding signal intensity to Microsoft Excel 2007. Secondly, a data alignment based on ascending m/z values from all samples was performed and signals originating from the culture media (e.g. CB or LB agar), the plastic tubes used for the lipid extractions as well as matrix background signals (recorded from blank samples) were subtracted. This leads to a data matrix of m/z values and the corresponding signal intensity found within all samples. Thirdly, the signal intensities of all peaks for each organism were normalized to the sum of signals (i.e. displayed as % relative intensity) and imported into the software programmes for cluster analysis.
  • the culture media e.g. CB or LB agar
  • FIG. 1 shows the extraction efficiency of 6 different organic solvents, for both charged phospholipids (PLs) and neutral lipids (NLs). The extraction efficiency is calculated based on the signal intensity of the corresponding lipid species in a MALDI-MS spectrum.
  • FIG. 3 shows three different mass spectra of the same lipid sample, containing a mixture of different lipid standards.
  • the spectra were obtained using different matrix substances according to the method described above. It can be seen that in the negative mode, 9AA-GUA allows detection of a large number of peaks. These correspond to anionic phospholipids.
  • the inventors assessed the selectivity of the three different matrix substances for ionization of the different major PL-classes present in biological membranes. The results are shown in FIG. 4 .
  • cationic PLs (PC and SM) from an equimolar PL-mixture are more readily ionised and detected than anionic PLs (e.g. PA, PE, PS), which were either not detectable or only showed weak signals ( FIG. 2A ).
  • ATT shows the best ionisation across the range of PLs tested in the positive ionisation mode.
  • anionic PLs e.g. PA, PE, PG, PS, PI, CL
  • PC and SM could not be detected
  • 9AA allowed an almost equal detection of all anionic PLs, whereas THAP and ATT showed prevalence for the ionization of PG and PS but not the other PL-classes.
  • ATT and 9AA revealed the preferential matrix substances for microbial lipid profiling in (+) and ( ⁇ ) ionization mode respectively. These are the preferred matrix components.
  • FIG. 5 shows the mass spectrum obtained from blood agar in the presence of a methanol lipid-extraction solvent. Several background peaks are seen in the lipid profiling mass range (m/z 700-1500) when measured in the (+)MALDI mode, but not in the ( ⁇ )MALDI mode.
  • blood agar contains some plasma lipids (e.g. derived from blood cells and lipoproteins) which are mostly cationic PL-species (mainly LPC, PC, and SM), and which are therefore preferentially detected in the (+) ionization mode
  • plasma lipids e.g. derived from blood cells and lipoproteins
  • cationic PL-species mainly LPC, PC, and SM
  • This problem can be circumvented in the (+)MALDI mode by using minimal medium (devoid of exogenous lipids) instead of blood agar.
  • minimal medium devoid of exogenous lipids
  • the resultant lipid mass spectrum is essentially the same, but with fewer culture medium contaminants.
  • the use of minimal medium generally leads to less favourable culture conditions, and results in longer incubation times to obtain a sufficient number of cells for analysis.
  • the ( ⁇ ) mode allows for blood agar to be used in cultivation, whilst minimizing signals from the agar.
  • the negative ionization mode allows detection of carboxylate anions resulting from dissociation of fatty acid residues that make up lipids. This can aid in microbial identification, as different strains comprise different FAs.
  • FIG. 6A shows a lipid MALDI-MS spectrum obtained according to the claimed method for an E. coli strain.
  • the inset shows 7 peaks which have been attributed to seven major FA-residues of the PLs recorded in the lipid extracts of E. coli.
  • the FA-composition of all intact PLs detectable in the ( ⁇ ) mode can be calculated using tandem mass spectrometry.
  • FIG. 6B shows the MS2 spectrum obtained by low-energy collision-induced dissociation (CID) analysis of the three most abundant signals (m/z 688.5, 702.5, 716.5) from the mass spectrum of FIG. 6A (indicated by asterisks).
  • CID collision-induced dissociation
  • each of the MS2 spectra contains only a selected number of the [RCOO]— ions detected in the MS1 mode. Based on this information the composition of the lipid species representing the three peaks could be identified as follows:
  • MALDI mass spectra were obtained by the claimed method of 9 different yeast strains belonging to Saccharomyces cerevisiae and Saccharomyces kudriavzevii.
  • the lipid composition of S. cerevisiae is well known [20] .
  • the peaks obtained by different spectra could therefore be readily assigned to particular lipids.
  • the reproducibility of the individual species within MALDI lipid profiles was measured as the relative signal intensity variation (RSIV) determined from the coefficient of variation (CV) of the individual peaks from NLs and PLs recorded from 4 independent sample preparations of the same organism using THAP, ATT and 9AA matrix in the (+) and ( ⁇ )MALDI mode. See FIGS. 12A to 12C .
  • RSIV relative signal intensity variation
  • Each of the lipid extracts was separately incorporated into ATT matrix, and a MALDI-MS spectrum was obtained in the positive mode. The results are shown in FIG. 7A .
  • Each of the lipid extracts was also separately incorporated into 9AA matrix, and a MALDI-MS spectrum was obtained in the negative mode. The results are shown in FIG. 7B .
  • E. coli represents a diverse group of Gram-bacteria closely related to other species (e.g. Enterobacter, Shigella, Salmonella, Klebsiella , etc.) belonging to the family of the “ Enterobacteriaceae ”, which typically live in the intestine of warm-blooded organisms (e.g. different mammalian species including humans).
  • FIG. 9 shows the ( ⁇ )MALDI mass spectra displayed in the m/z range 240-400 and 650-800 of four E. coil strains.
  • FIG. 9A Inspection of the FA-profile (i.e. based on detection of the [RCOO]— ions) by MALDI-QIT-TOF-MS/MS ( FIG. 9A ) shows that these differences can mainly be attributed to a different content of 17:1 (cy17:0) and 18:1 representing the major FA residues of the peaks at m/z 702 and 716 ( FIG. 9B ) indicated by circles.
  • the antibiotic sensitive strain (#7) can be clearly differentiated from the antibiotic resistant strains (#9, #10) and the enteropathogenic strains EIEC (#11), EAEC (#12) and EPEC (#13), respectively.
  • MST minimal spanning tree
  • FIG. 13 shows an “all-in-one” microorganism identification approach (lipid fingerprinting and protein fingerprinting of the same microbes) utilising a rapid single-step extraction ( ⁇ 5-10 min dependent on the rigidity of the cell wall structure) using MeOH or EtOH and ultrasonication.
  • a homogenous suspension of hydrophilic and hydrophobic molecules i.e. mainly cellular proteins and membrane lipids
  • MALDI matrix systems e.g. CHCA for proteins; ATT or 9AA for lipids
  • MALDI-MS analysis in positive and/or negative mode.
  • the obtained MS data are searched against a database using bioinformatic software tools (e.g. multivariate data analysis).
  • FIGS. 14 and 15 show the improvements of the single-step extraction for lipid analysis of bacteria by MALDI-MS.
  • high-quality mass spectra from Gram- ( FIG. 14A ) and Gram+ ( FIG. 14B ) bacteria can be obtained in shorter time than using conventional protocols (5 minutes ultrasonication vs. 30 minutes on ice with vortexing) which makes it more suitable for routine work (e.g. in clinical labs).
  • additional lipid species e.g. Lysyl-PG from S. aureus
  • the use of e.g. MeOH or EtOH improves the quality of mass spectra ( FIGS. 15A and 15B ) and reduces the contribution of background signals (e.g. “plastic peaks”) compared to conventional solvents (e.g. CHCl 3 ) used for lipid extraction ( FIG. 15C ).
  • FIGS. 16 to 18 demonstrate advantages of the “all-in-one” approach for the identification of bacteria.
  • FIGS. 19 to 21 demonstrate the advantages of the “all-in-one” approach for the identification of fungi.
  • FIG. 19 the SARAMIS search results of different yeasts and filamentous fungi are shown. It can be seen that the confirmation level (column headed “%”) (even after protein extraction of the cells) was either very bad or that in many cases no useful mass spectrum for identification was available.
  • This demonstrates the general problem of proteintyping for the identification of yeasts and especially filamentous fungi which contain more rigid cell wall structures compared to most of the bacteria.
  • FIG. 20 using the lipid mass spectra in the positive mode following the single-step extraction protocol ( FIG. 20 ) a nice differentiation of the yeasts (e.g. Saccharomyces ) and different filamentous fungi (e.g. Aspergillus, Penicillium, Trichoderma , etc.) was obtained ( FIG. 21 ).
  • FIGS. 22 and 23 show the protein m/z range for the samples corresponding to the protein analysis of FIG. 16 .
  • Good signal to noise and peak resolution facilitates high confidence levels (% value in FIG. 16 ).
  • the present inventors have acquired a protein mass spectrum of Saccharomyces cerevisiae (using a CHCA matrix) and a lipid mass spectrum of the same microbe (using a ATT matrix) and then combined/merged them. Specifically, by combining lipid data from the m/z range of 500 to 900 with protein data from the m/z range of 2000 to 15000 a merged data set in the m/z range 500 to 15000 was obtained. Cluster analysis based on this merged mass data enabled strain-level identification.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Sampling And Sample Adjustment (AREA)
US15/028,052 2013-10-09 2014-10-09 Microbial analysis Active US10655157B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1317837.1 2013-10-09
GBGB1317837.1A GB201317837D0 (en) 2013-10-09 2013-10-09 Microbial analysis
PCT/GB2014/053043 WO2015052525A1 (en) 2013-10-09 2014-10-09 Microbial analysis

Publications (2)

Publication Number Publication Date
US20160237469A1 US20160237469A1 (en) 2016-08-18
US10655157B2 true US10655157B2 (en) 2020-05-19

Family

ID=49630403

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/028,052 Active US10655157B2 (en) 2013-10-09 2014-10-09 Microbial analysis

Country Status (6)

Country Link
US (1) US10655157B2 (zh)
EP (2) EP3055420B1 (zh)
JP (2) JP2016533715A (zh)
CN (1) CN106133149B (zh)
GB (4) GB201317837D0 (zh)
WO (1) WO2015052525A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101834720B1 (ko) * 2016-11-03 2018-03-06 (주)바이오니아 매트릭스 도움 레이저 탈착／이온화 질량분석 방법
KR20180051912A (ko) * 2016-11-09 2018-05-17 (주)바이오니아 매트릭스 도움 레이저 탈착／이온화 질량분석용 시료 플레이트 및 이를 이용한 질량분석 방법
US20210102953A1 (en) * 2018-04-16 2021-04-08 Shimadzu Corporation Mass spectrometry kit, microorganism identification kit, sample preparation method, analysis method, and microorganism identification method
JP7305926B2 (ja) * 2018-06-08 2023-07-11 株式会社島津製作所 分析方法、質量分析用試料調製用材料、質量分析用キット、糖鎖類分析用材料および糖鎖類質量分析用キット
GB2582135B (en) 2019-03-11 2023-06-21 Kratos Analytical Ltd Mass spectrometry apparatus
WO2021035009A1 (en) * 2019-08-20 2021-02-25 Pattern Bioscience, Inc. Methods for screening and subsequent processing of samples taken from non-sterile sites
JP7302524B2 (ja) * 2020-04-23 2023-07-04 株式会社島津製作所 微生物分析方法
JP7384358B2 (ja) * 2020-04-27 2023-11-21 株式会社島津製作所 有機化合物の構造解析方法
WO2024034453A1 (ja) * 2022-08-12 2024-02-15 株式会社島津製作所 マトリックス溶液、質量分析方法、記憶媒体、判別方法

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10038694A1 (de) 2000-07-28 2002-02-14 Anagnostec Ges Fuer Analytisch Verfahren zur Identifizierung von Mikroorganismen mittels MALDI-TOF-MS
US20040214259A1 (en) 2003-02-28 2004-10-28 The University Of Tennessee Research Foundation Methods of sampling microbial communities and apparatus therefore
US20050035284A1 (en) 2003-06-06 2005-02-17 Ionwerks, Inc. Gold implantation/deposition of biological samples for laser desorption three dimensional depth profiling of tissues
JP2007309695A (ja) 2006-05-16 2007-11-29 Univ Of Tokyo 質量分析のための脂質修飾ペプチドの抽出方法
US20070275478A1 (en) 2006-05-26 2007-11-29 Science & Engineering Services, Inc. Method and apparatus for processing of biological samples for mass spectrometry analysis
US20080108104A1 (en) 2006-11-02 2008-05-08 Colorado State University Research Foundation Identification of bacterial species and subspecies using lipids
US20080187907A1 (en) 2004-02-26 2008-08-07 Bartholomew Calvin H Catalytic Production of Biomakers From Biological Materials
WO2010020812A1 (en) 2008-08-20 2010-02-25 Roar Particles Uk Limited Identification of sample components
US20100116980A1 (en) 2007-01-08 2010-05-13 Xavier Nassif Means for identifying a strain isolated from a clinical sample at the species and/or subspecies level
CN102033114A (zh) 2010-10-12 2011-04-27 四川大学 一种快速简便分析传统酿造用大曲微生物群落结构的方法
WO2012016929A1 (en) 2010-08-02 2012-02-09 Bruker Daltonik Gmbh Mass spectrometric diagnosis of sepsis without blood culture
US20120197535A1 (en) 2011-01-03 2012-08-02 Goodlett David R Methods for identifying bacteria
CN102706952A (zh) 2011-11-29 2012-10-03 中国科学院化学研究所 萘乙二胺无机酸盐或萘乙二胺有机酸盐在作为maldi中基质的应用
US20130146758A1 (en) 2010-05-21 2013-06-13 Empa Eidg. Materialprufungs-Und Forschungsanstalt High-density sample support plate for automated sample aliquoting

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102262139A (zh) * 2011-04-28 2011-11-30 华南理工大学 一种发现和鉴定单细胞藻类脂质生物标志物的方法
CN102253111A (zh) * 2011-06-09 2011-11-23 曹际娟 Maldi-tof ms辅助鉴定单增李斯特氏菌的方法

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10038694A1 (de) 2000-07-28 2002-02-14 Anagnostec Ges Fuer Analytisch Verfahren zur Identifizierung von Mikroorganismen mittels MALDI-TOF-MS
US20040214259A1 (en) 2003-02-28 2004-10-28 The University Of Tennessee Research Foundation Methods of sampling microbial communities and apparatus therefore
US20050035284A1 (en) 2003-06-06 2005-02-17 Ionwerks, Inc. Gold implantation/deposition of biological samples for laser desorption three dimensional depth profiling of tissues
US20080187907A1 (en) 2004-02-26 2008-08-07 Bartholomew Calvin H Catalytic Production of Biomakers From Biological Materials
JP2007309695A (ja) 2006-05-16 2007-11-29 Univ Of Tokyo 質量分析のための脂質修飾ペプチドの抽出方法
US20070275478A1 (en) 2006-05-26 2007-11-29 Science & Engineering Services, Inc. Method and apparatus for processing of biological samples for mass spectrometry analysis
US20080108104A1 (en) 2006-11-02 2008-05-08 Colorado State University Research Foundation Identification of bacterial species and subspecies using lipids
US20100116980A1 (en) 2007-01-08 2010-05-13 Xavier Nassif Means for identifying a strain isolated from a clinical sample at the species and/or subspecies level
WO2010020812A1 (en) 2008-08-20 2010-02-25 Roar Particles Uk Limited Identification of sample components
US20130146758A1 (en) 2010-05-21 2013-06-13 Empa Eidg. Materialprufungs-Und Forschungsanstalt High-density sample support plate for automated sample aliquoting
WO2012016929A1 (en) 2010-08-02 2012-02-09 Bruker Daltonik Gmbh Mass spectrometric diagnosis of sepsis without blood culture
CN102033114A (zh) 2010-10-12 2011-04-27 四川大学 一种快速简便分析传统酿造用大曲微生物群落结构的方法
US20120197535A1 (en) 2011-01-03 2012-08-02 Goodlett David R Methods for identifying bacteria
CN102706952A (zh) 2011-11-29 2012-10-03 中国科学院化学研究所 萘乙二胺无机酸盐或萘乙二胺有机酸盐在作为maldi中基质的应用

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
Alex Van Belkum et al., "Biomedical Mass Spectrometry in Today's and Tomorrow's Clinical Microbiology Laboratories", Journal of Clinical Microbiology, 2012, pp. 1513-1517, vol. 50, No. 5.
Anne M. Distler et al., "Mass spectrometric detection of protein, lipid and heme components of cytochrome c oxidase from R. sphaeroides and the stabilization of non-covalent complexes from the enzyme", Eur. J. Mass Spectrom., 2004. pp. 295-308, vol. 10.
Asmaa El Hamidi et al., "Microextraction of bacterial lipid A: easy and rapid method for mass spectrometric characterization", Journal of Lipid Research, 2005, pp. 1773-1778, vol. 46.
C.D. Calvano et al., "1,8-Bis(dimethylamino)naphthalene/9-aminoacridine: A new binary matrix for lipid fingerprinting of intact bacteria by matrix assisted laser desorption ionization mass spectrometry", Analytica Chimica Acta, 2013, pp. 56-63, vol. 798.
Cosima D. Calvano et al., "Lipid fingerprinting of Gram-positive lactobacilli by intact cells-matrix-assisted laser desorption/ionization mass spectrometry using a proton sponge based matrix", Rapid Commun. Mass Spectrom., 2011, pp. 1757-1764, vol. 25.
Cosima D. Calvano et al., "Lipid fingerprinting of Gram-positive lactobacilli by intact cells—matrix-assisted laser desorption/ionization mass spectrometry using a proton sponge based matrix", Rapid Commun. Mass Spectrom., 2011, pp. 1757-1764, vol. 25.
Elzbieta Brzuszkiewicz et al., "Genome sequence analyses of two isolates from the recent Escherichia coli outbreak in Germany reveal the emergence of a new pathotype: Entero-Aggregative-Haemorrhagic Escherichia coli (EAHEC)", Arch Microbiol, 2011, pp. 883-891, vol. 193.
Erin Maloney et al., "The Two-Domain LysX Protein of Mycobacterium tuberculosis is Required for Production of Lysinylated Phosphatidylglycerol and Resistance to Cationic Antimicrobial Peptides", PLoS Pathogens, Jul. 2009, pp. 1-13, vol. 5, Issue 7.
Gang Sun et al., "Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometric Analysis of Cellular Glycerophospholipids Enabled by Multiplexed Solvent Dependent Analyte-Matrix Interactions", Anal. Chem., 2008, pp. 7576-7585, vol. 80.
Gerald Stübiger et al., "Analysis of Lipids Using 2,4,6-Trihydroxyacetophenone as a Matrix for MALDI Mass Spectrometry", Anal. Chem., 2007, pp. 3206-3213, vol. 79.
Gerald Stübiger et al., "Analysis of Oxidized Phospholipids by MALDI Mass Spectrometry Using 6-Aza-2-thiothymine Together with Matrix Additives and Disposable Target Surfaces ", Anal. Chem., 2010, pp. 5502-5510, vol. 82.
Gregory E. Sims et al., "Whole-genome phylogeny of Escherichia coli/Shigella group by feature frequency profiles (FFPs)", PNAS Early Edition, pp. 1-6.
International Search Report for PCT/GB2014/053043 dated Jan. 12, 2015.
Jackson O. Lay, Jr. "Characterization of Lipids by MALDI Mass Spectrometry", The AOCS Lipid Library, 7 pgs., Available at http://lipidlibrary.aocs.org/lipidomics/maldi-lay/index.htm.
James P. Nataro et al., "Diarrheagenic Escherichia coli", Clinical Microbiology Reviews, Jan. 1998, pp. 142-201, vol. 11, No. 1.
Jeffrey J. Jones et al., "Investigation of MALDI-TOF and FT-MS techniques for analysis of Escherichia coli whole cells", Analytical Chemistry, 2003, vol. 75, pp. 1340-1347.
Jennifer Gidden et al., "Lipid compositions in Escherichia coliand Bacillus subtilis during growth as determined by MALDI-TOF and TOF/TOF mass spectrometry", International Journal of Mass Spectrometry, 2009, pp. 178-184, vol. 283.
Jiang Qian et al., "MALDI-TOF mass signatures for differentiation of yeast species, strain grouping and monitoring of morphogenesis markers", Anal. Bioanal Chem., pp. 439-449, vol. 392.
John D. Leszyk, "Evaluation of the New MALDI Matrix 4-Chloro-a-Cyanocinnamic Acid", Journal of Biomolecular Techniques, 2010, vol. 21, pp. 81-91.
John P. Anhalt et al., "Identification of Bacteria Using Mass Spectrometry", Analytical Chemistry, Feb. 2, 1975, pp. 219-225, vol. 47, No. 2.
Justin M. Hettick et al., "Proteomic Profiling of Intact Mycobacteria by Matrix-Assisted Laser Desorption/lonization Time-of-Flight Mass Spectrometry", Analytical Chemistry, 2004, vol. 76, pp. 5769-5776.
Karlheinz Grillitsch et al., "Lipid particles/droplets of the yeast Saccharomyces cerevisiae revisited: Lipidome meets Proteome", Biochimica et Biophysica Acta, 2011, vol. 1811, pp. 1811 11651176.
Marta Palusinska-Szysz et al., "Legionella bozemanae synthesizes phosphatidylcholine from exogenous choline", Microbiological Research, 2011, pp. 87-98, vol. 166.
Martin A. Claydon et al., "The rapid identification of intact microorganisms using mass spectrometry", Nature Biotechnology, Nov. 1996, pp. 1584-1586, vol. 14.
Oksana Lukjancenko et al., "Comparison of 61 Sequenced Escherichia coli Genomes", Microb Ecol, 2010, pp. 708-720, vol. 60.
Powell, D.W. et al. Cluster Analysis of Mass Spectrometry Data Reveals a Novel Component of SAGA, Molecular and Cellular Biology, vol. 24(6), pp. 7249-7259 (Year: 2004). *
R. Vitale et al., "Lipid fingerprints of intact viruses by MALDI-TOF/mass spectrometry" Biochimica et Biophysica Acta, 2013, vol. 1831, pp. 872-879.
Rachal L. Vermillion-Salsbury et al., "9-Aminoacridine as a matrix for negative mode matrix-assisted laser desorption-ionization", Rapid Communications in Mass Spectrometry, 2002, pp. 1575-1581, vol. 16.
Rishi Singhal et al., "MALDI profiles of proteins and lipids for the rapid characterisation of upper GI-tract cancers", Journal of Protoemics, 2013, pp. 207-215, vol. 80.
Roberto Angelini et al., "MALDI-TOF/MS analysis of archaebacterial lipids in lyophilized membranes dry-mixed with 9-aminoacridine", Journal of Lipid Research, 2010, pp. 2818-2825, vol. 51.
S. G. Batrakov et al., "Unusual fatty acid composition of cerebrosides from the filamentous soil fungus Mortierella alpine", Chemistry and Physics of Lipids, 2002, vol. 117, pp. 45-51.
S. Mariccor A.B. Batoy et al., "Lipid and Phospholipid Profiling of Biological Samples Using MALDI Fourier Transform Mass Spectrometry", Lipids, 2009, pp. 367-371, vol. 44.
Suresh Kumar Kailasa et al., "Surface modified BaTiO3 nanopartides as the matrix for phospholipids and as extracting probes for LLME of hydrophobic proteins in Escherichia coli by MALDI-MS", Talanta, 2013, vol. 114, pp. 283-290.
Teresa C. Cain et al., "Differentiation of Bacteria Using Protein Profiles from Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry", Rapid Communications in Mass Spectrometry, 1994, pp. 1026-1030, vol. 8.
UK Search Report for GB1317837.1 dated Jun. 23, 2014.
UK Search Report for GB1417899.0 dated Jul. 31, 2015.
Vermillion-Salsbury, R. L. 9-Aminoacridine as a Matrix for negative mode matrix-assisted laser desorption/ionization, 2002, Rapid Communication in Mass Spectrmetry, vol. 16, pp. 1575-1581. *
Vitali Matyash et al., "Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics", Journal of Lipid Research, 2008, pp. 1137-1146, vol. 49.
Written Opinion for PCT/GB2014/053043 dated Jan. 12, 2015.
Xi Shu et al., "Rapid lipid profiling of bacteria by online MALDI-TOF mass spectrometry", International Journal of Mass Spectrometry, 2012, pp. 71-76, vol. 321-322.
Xu, S. et al. Matrix with High Salt Tolerance for the Analysis of Peptide and Protein Samples by Desorption/Ionization Time-of-Flight Mass Spectrometry, Analytical Chemistry, vol. 78, pp. 2593-2599 (Year: 2006). *
Yanyan Li et al., "A rapid one-step method for the characterization of membrane lipid remodeling in Francisella using matrix-assisted laser desorption ionization time-of-flight tandem mass spectrometry", Rapid. Commun. Mass Spectrom., 2011, pp. 2641-2648, vol. 25.
Ying S. Ting et al., "Automated Lipid A Structure Assignment from Hierarchical Tandem Mass Spectrometry Data", J. Am. Soc. Mass Spectrom., 2011, pp. 856-866, vol. 22.
Zhao, Z. et al. An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples, 2010, Journal of Lipid Research, vol. 51, pp. 652-659. *
Zhenwen Zhao et al., "An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples", Journal of Lipid Research, 2010, vol. 51.
Zhou, P., et al. Study of Matrix Additives for Sensitive Analysis of Lipid A by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry, 2010, Applied and Environmental Microbiology, vol. 76(11), pp. 3437-3443. *

Also Published As

Publication number Publication date
GB2524854A (en) 2015-10-07
EP3055420A1 (en) 2016-08-17
EP3456838B1 (en) 2020-05-13
JP6918875B2 (ja) 2021-08-11
US20160237469A1 (en) 2016-08-18
GB2558426A (en) 2018-07-11
WO2015052525A1 (en) 2015-04-16
GB2558425A (en) 2018-07-11
GB2558426B (en) 2018-09-26
JP2020038208A (ja) 2020-03-12
GB2558425B (en) 2018-09-26
CN106133149B (zh) 2021-04-30
GB201800188D0 (en) 2018-02-21
GB2524854B (en) 2018-03-14
EP3055420B1 (en) 2019-01-02
GB201417899D0 (en) 2014-11-26
GB201317837D0 (en) 2013-11-20
JP2016533715A (ja) 2016-11-04
GB201800190D0 (en) 2018-02-21
EP3456838A1 (en) 2019-03-20
CN106133149A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
US10655157B2 (en) Microbial analysis
US20220412988A1 (en) Mass spectrometric identification of microorganisms in complex samples
Croxatto et al. Applications of MALDI-TOF mass spectrometry in clinical diagnostic microbiology
Vaidyanathan et al. Flow-injection electrospray ionization mass spectrometry of crude cell extracts for high-throughput bacterial identification
Pennanec et al. A quick and easy method to identify bacteria by matrix‐assisted laser desorption/ionisation time‐of‐flight mass spectrometry
JP2013528387A (ja) 微生物の薬物耐性を判定するシステムおよび方法
Reich et al. Species identification of bacteria and fungi from solid and liquid culture media by MALDI-TOF mass spectrometry
US20150024428A1 (en) METHOD OF IDENTIFICATION OF SPORE-FORMING Bacillus spp. BY DIRECT In-situ ANALYSIS OF MALDI-TOF MASS SPECTROMETRY, AND ANALYSIS SYSTEM
Shu et al. Lipid fingerprinting of Bacillus spp. using online MALDI-TOF mass spectrometry
US11754572B2 (en) Mass spectrophotometric detection of microbes
WO2018112165A1 (en) Methods for lipid extraction and identification of microbes using same via mass spectrometry
Ahmad et al. High-resolution MALDI-TOF mass spectrometry of bacterial proteins using a Tris-EDTA buffer approach
US20030027231A1 (en) Methods for using mass spectrometry to identify and classify filamentous fungi, yeasts, molds and pollen
AU2001264867A1 (en) Methods for using mass spectrometry to identify and classify filamentous fungi, yeasts, molds and pollen
Arendowski et al. Study of sample preparation influence on bacterial lipids profile in matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry
Theel Matrix-assisted laser desorption ionization-time of flight mass spectrometry for the identification of bacterial and fungal isolates
Basile et al. Methods and instrumentation in mass spectrometry for the differentiation of closely related microorganisms
US20240242950A1 (en) Bio-identification using low resolution tandem mas spectrometry
Meyer et al. Mass spectrometry: A powerful tool for the identification of wine-related bacteria and yeasts
Cox et al. Mass Spectrometry and Microbial Diagnostics in the Clinical Laboratory
Zhu Mass Spectrometry Methods for Bacterial Infection Diagnosis and Cancer Analysis
Kostrzewa Biotyping of Microorganisms
Zhu et al. MALDI-TOF Mass Fingerprinting for Rapid Identification of Bacteria: Experimental Procedures
Drucker Fast atom bombardment-mass spectrometry
Kelman Investigating mycotoxins and secondary metabolites in Canadian agricultural commodities using high-resolution mass spectrometry

Legal Events

Date Code Title Description
AS Assignment

Owner name: KRATOS ANALYTICAL LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STUBER, GERALD;BELGACEM, OMAR;SIGNING DATES FROM 20140408 TO 20150112;REEL/FRAME:038225/0171

AS Assignment

Owner name: KRATOS ANALYTICAL LIMITED, UNITED KINGDOM

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE LAST NAME OF THE FIRST INVENTOR PREVIOUSLY RECORDED ON REEL 038225 FRAME 0171. ASSIGNOR(S) HEREBY CONFIRMS THE EXECUTED ASSIGNMENT;ASSIGNORS:STUBIGER, GERALD;BELGACEM, OMAR;SIGNING DATES FROM 20140408 TO 20150112;REEL/FRAME:038400/0001

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4